Elevations in the Mitochondrial Matrix Protein Cyclophilin D Correlate With Reduced Parvalbumin Expression in the

John T O'Brien1, Sophia P Jalilvand1, Neha A Suji1

  • 1School of Behavioral and Brain Sciences, The University of Texas at Dallas, Richardson, TX, USA.

Schizophrenia Bulletin
|February 27, 2024
PubMed
Abstract

Insights

Schizophrenia involves dorsolateral prefrontal cortex (DLPFC) dysfunction. This study found elevated cyclophilin D (CypD) in parvalbumin interneurons (PVIs) in schizophrenia patients, potentially explaining PVI dysfunction and cognitive deficits.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Cell Biology

Background:

  • Cognitive deficits in schizophrenia are linked to dorsolateral prefrontal cortex (DLPFC) dysfunction.
  • Alterations in parvalbumin (PV)-expressing interneurons (PVIs) are implicated in schizophrenia.
  • Redox dysregulation and oxidative stress may contribute to GABAergic interneuron dysfunction and PV loss.

Purpose of the Study:

  • To investigate the role of cyclophilin D (CypD), a mitochondrial protein, in PVI alterations in the DLPFC of individuals with schizophrenia.
  • To determine if CypD levels are altered in PVIs in schizophrenia and correlate with PV levels and PVI numbers.

Main Methods:

  • Western blotting to measure CypD protein levels in postmortem DLPFC specimens from schizophrenic patients and controls.
  • Multilabel immunofluorescent confocal microscopy to quantify PVI numbers and PV and CypD protein levels in specific cortical layers.

Main Results:

  • No significant alteration in the overall number of PVIs in the DLPFC of schizophrenic patients.
  • Decreased PV protein levels in individual PVIs of layers 2-4 along a superficial-to-deep gradient in schizophrenic patients.
  • Significant elevations in CypD in both PVIs and total DLPFC gray matter in schizophrenic patients.

Conclusions:

  • Findings support previously reported PVI anomalies in schizophrenia.
  • CypD-mediated mitochondrial permeability transition pore (mPTP) formation is a potential contributor to PVI dysfunction in schizophrenia.
  • This suggests a novel therapeutic target for schizophrenia treatment.